The US Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals Inc's Abbreviated New Drug Application (ANDA) for eprosartan mesylate tablets, 400 mg (base) and 600 mg (base). This product is the generic version of Abbott Laboratories' Teveten tablets, which are used to treat hypertension.

Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification to the FDA for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base), and was awarded 180 days of marketing exclusivity. Mylan is shipping this product immediately.

Eprosartan Mesylate tablets, 400 mg (base) and 600 mg (base), had US sales of approximately $4.9 million for the 12 months ending Sept. 30, 2011, according to IMS Health.

Currently, Mylan has 170 ANDAs pending FDA approval representing $98.4 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.8 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. is the leading generic and specialty pharmaceutical companies in the world focused on respiratory, allergy and psychiatric therapies.